Severe aplastic anemia (SAA) is a life threatening BM failure and the preferred therapy for children is allogeneic hematopoietic SCT (HSCT) with an HLA-matched sibling donor. Immunosuppressive therapy with anti-thymocyte globulin (ATG) and CsA is an alternative for patients lacking an HLA-identical donor. For many years, horse ATG (hATG) was the preferred source, but in Europe the production of hATG ended in 2007, and hATG was replaced by rabbit ATG (rATG). Recently, Scheinberg et al. 1 published a randomized trial comparing rATG with hATG in SAA patients and concluded that hematological response and survival using hATG was superior to rATG. Here, we report in a pediatric SAA transplant cohort that the use of rATG as first-line therapy, followed by rATG in the HSCT conditioning regimen, can result in severe transplant-related problems.
Sensitization toward ATG, defined as production of anti-ATG Abs, has been observed in SAA patients as well as in solid organ and HSCT recipients.
2 --4 When a second immunosuppressive course is required or in vivo T-cell depletion is needed in the context of HSCT, a switch from hATG to rATG is advisable to lower the risk of adverse reactions due to the potential presence of anti-hATG Abs. 5 A total of 8 out of 18 SAA patients, transplanted in our transplant-center between 1998 and 2008, received an upfront immunosuppressive therapy with at least one course of rATG (median 8.5 months, range 6 --48 months before HSCT), followed by HSCT conditioning containing rATG. In 75% of the SAA patients (six out of eight) with prior rATG treatment, IgG and/or IgA antirATG Abs were detectable in serum obtained before the start of HSCT conditioning, whereas IgM anti-rATG Abs were absent. AntirATG antibodies were undetectable in 10 patients without upfront rATG treatment prior to HSCT. Conditioning regimens, graft, donor details and rATG infusion-related side effects of the six patients with Abs against rATG are summarized in Table 1 . rATG administration (2.5 mg/kg per day) was initiated at day À5. All patients received anti-histamines and high-dose steroids starting 24 h prior to the first rATG infusion.
In three out of the six patients with anti-rATG Abs, an immediate systemic inflammatory response syndrome was encountered upon the first infusion of rATG, which necessitated a switch from rATG to alemtuzumab. Serum rATG was rapidly and completely cleared in these switched patients, that is, at day þ 5 after transplantation, rATG was not detectable anymore (data not shown). In a group of 15 non-SAA HSCT recipients, who also received only one dose of rATG, but had no anti-rATG antibodies prior to HSCT, the median concentration of total rATG at day þ 5 was 14 mg/mL (range 9.1 --19.7 mg/mL) (Po0.001), indicating that anti-rATG antibodies cause a rapid clearance of rATG. Despite the rapid rATG clearance, IgG (and IgA) anti-rATG of recipient G1m allotype persisted for periods of 3 up to 20 months after HSCT in these three SAA patients ( Table 1) .
The remaining three patients with IgG or IgA anti-rATG prior to HSCT completed their rATG schedule, despite side effects during the ATG infusions. One patient (unique patient number (UPN) 691) produced a strong anti-rATG response consisting of IgM, IgA and recipient allotype IgG antibodies from day þ 3 after HSCT onwards (Figure 1b ), resulting in a complete rATG clearance on day þ 6 (Figure 1a ). This Ab rise coincided with skin rash and fever. Autologous T cells were detected at day þ 12 and graft rejection followed subsequently (Figure 1c ). At day þ 28, the patient was successfully re-transplanted with a second graft from the mother.
In a second patient (UPN 473), IgG anti-rATG present prior to HSCT disappeared very fast from the circulation, but at day þ 17 after HSCT a new anti-rATG response was noticed, that is, IgM and IgA anti-ATG developed in combination with a switch from high (relative avidity index: 1.48 M) to low (avidity index: 0.28 M) avidity IgG anti-rATG antibodies. 6 This IgG anti-rATG was of donor G1 m allotype. The anti-rATG response coincided with a steep decrease of serum rATG (data not shown) and the patient developed severe acute GVHD, grade III at day þ 23. In the third sensitized patient completing a full course of rATG (UPN 460), no anti-rATG antibodies were detectable after HSCT.
There are no data on the actual sensitization rate in patients who receive rATG both for upfront and subsequent treatment. 5 Humanized MoAbs, such as alemtuzumab, 7 could be an alternative for sensitized SAA patients. However, with a longer serum half-life, alemtuzumab may seriously delay T-cell reconstitution, and subsequently extend the immunocompromized state. 8, 9 Previous exposure to ATG predisposes to the development of Abs against ATG, and to serum sickness. 10, 11 IgG Anti-ATG leads to a faster clearance and lower ATG levels may lead to either rejection or acute GVHD, as we know from transplanted patients not receiving ATG. 12 In SAA patients, serum sickness is reported to be associated with poorer outcome. 2 In our cohort, severe side effects upon the first rATG infusion given as part of the conditioning necessitated a switch to alemtuzumab in three out of six sensitized patients. This need for a switch to alemtuzumab is significantly more frequent than in a cohort of patients, including 10 not-rATG sensitized SAA patients, who did not receive any ATG therapy before HSCT conditioning. (15 out of 96; P ¼ 0.03; unpublished observations).
Residual plasma cells of recipient origin were the producers of anti-rATG Abs after HSCT in four of the six SAA patients; in another case there was no informative G1m allotype difference between donor and recipient. In contrast, in UPN 473 who received a nondepleted BM graft after a conditioning regimen with a full course of rATG, the anti-rATG response after HSCT was derived from B cells of donor origin. Recently, we reported the increased risk of acute GVHD in patients with an IgG anti-ATG response early after HSCT. 12 Such a response occurred in 4 out of 59 (7%) of non-sensitized pediatric recipients of a full graft.
On the basis of present findings, it is strongly recommended to screen for anti-ATG antibodies in ATG-pretreated patients and, if positive, to choose an alternative anti-T-cell therapy, that is, alemtuzumab, for their transplantation conditioning. Using this approach, severe adverse reactions upon ATG administration and major clinical complications early after HSCT may be prevented in ATG-sensitized patients. Letter to the Editor
